Compounding HRT Solutions for Hormonal Acne Patients

According to NIH MedlinePlus and ACOG, in hormonal acne, painful deep cystic lesions may present as firm or fluctuant nodules situated beneath the skin surface, commonly clustered along the jawline and chin. These lesions are typically deep and cystic, tender to touch, erythematous, and may feel warm; they often do not progress to a whitehead and may recur in cyclical patterns. According to NIH MedlinePlus, unresolved deep inflammatory acne lesions may result in post-inflammatory hyperpigmentation or scarring. Patients experiencing severe, rapidly worsening, or unusually painful nodular lesions should seek evaluation from a qualified clinician.

According to ACOG and NIH MedlinePlus, in hormonal acne, breakouts that flare around the menstrual cycle may reflect cyclical shifts in estrogen and progesterone that influence sebaceous gland activity and follicular keratinization. According to ACOG, perimenstrual androgen surges may contribute to increased sebum production and inflammatory lesion formation in susceptible individuals. Patients who notice a consistent pattern of acne worsening in the days before or during menstruation should discuss this pattern with a qualified clinician, as it may indicate an underlying hormonal contributor warranting further evaluation.

According to NIH MedlinePlus, in hormonal acne, oily skin with persistent clogged pores may reflect excess sebum production driven by androgen activity on the sebaceous glands. Pores may appear enlarged and remain filled with oxidized debris, producing stubborn blackheads; patients may also notice tactile roughness and small raised bumps associated with follicular hyperkeratinization. According to ACOG, cyclical flare patterns tied to fluctuating androgens are common, often concentrated on the T-zone and jawline. Patients with persistent or worsening oily skin and comedonal acne that does not respond to topical measures should seek evaluation from a qualified clinician.

According to NIH MedlinePlus and ACOG, persistent or worsening acne into the late 20s and beyond may reflect hormonal drivers in which cyclic increases in androgens stimulate sebaceous gland enlargement, increased oil production, and thickened follicular lining, producing stubborn comedones, inflamed papules, and deeper painful nodules. Lesions commonly cluster around the lower face — chin, jawline, and neck — and may flare with menstrual cycles, recur in crops, and leave dark marks and altered skin texture. According to ACOG, this pattern differs from adolescent acne and may indicate an underlying endocrine or gynecologic contributor. Patients experiencing this presentation should seek evaluation from a qualified clinician.

According to the FDA-approved prescribing information for Spironolactone, Spironolactone is a potassium-sparing diuretic and aldosterone antagonist indicated for conditions including edema, hypertension, and primary hyperaldosteronism; the prescribing information also describes its off-label discussion in the context of androgen-mediated conditions in women. The labeling describes that Spironolactone may antagonize androgen receptors and reduce aldosterone-mediated effects, and notes that it may affect sebaceous gland activity in androgen-sensitive tissue. Per the labeling, use may require monitoring of serum potassium levels, and Spironolactone is contraindicated in pregnancy due to potential endocrine effects on a male fetus; menstrual irregularities and diuresis may occur. Any compounded preparation involving Spironolactone is not reviewed by FDA for safety or effectiveness before dispensing. Commercially available Spironolactone products are separately regulated, and clinical decisions about its use belong with the prescribing clinician.

According to the FDA-approved prescribing information for Cyproterone acetate-ethinyl estradiol, Cyproterone acetate-ethinyl estradiol is a combined hormonal preparation pairing the antiandrogenic progestin cyproterone acetate with ethinyl estradiol; the prescribing information describes its use in conditions driven by androgen excess, including certain acne presentations, where it may lower ovarian and adrenal androgen levels and block androgen receptors in sebaceous gland tissue, reducing sebum production and follicular plugging. Per the labeling, use may be associated with risks including venous thromboembolism and hepatic effects, and the prescribing information contains boxed warning language; patients should be aware of applicable contraindications including pregnancy. Any compounded preparation involving Cyproterone acetate-ethinyl estradiol is not reviewed by FDA for safety or effectiveness before dispensing. Commercially available Cyproterone acetate-ethinyl estradiol products are separately regulated, and clinical decisions about their use belong with the prescribing clinician.